Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplerenone in Presymptomatic Phospholamban R14del Carriers
NCT01857856Phase 3Completed
- Start
- May 2013
- Primary completion
- Oct 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of eplerenone in cardiomyopathy (2 arms). Primary endpoints: Left ventricular enddiastolic volume at 3 years, Left ventricular ejection fraction at 3 years and 8 more. Started May 2013; status: completed.
02
Drugs
eplerenone
03
Conditions
cardiomyopathy
Beyond the preview
Go deeper on NCT01857856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01857856.